BioNTech (NASDAQ:BNTX) Upgraded at Truist Financial

Truist Financial upgraded shares of BioNTech (NASDAQ:BNTX) to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

Several other research analysts have also recently commented on the stock. TD Cowen decreased their target price on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a research report on Wednesday, March 11th. Bank of America reaffirmed a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research report on Tuesday, March 10th. Citigroup reduced their target price on BioNTech from $145.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. Finally, Morgan Stanley cut their price objective on BioNTech from $134.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $133.73.

BioNTech Price Performance

BNTX opened at $85.68 on Wednesday. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a market cap of $20.56 billion, a P/E ratio of -16.35 and a beta of 1.51. The company has a 50 day moving average of $103.70 and a two-hundred day moving average of $101.60.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new position in shares of BioNTech in the fourth quarter valued at about $4,969,000. Rockefeller Capital Management L.P. raised its stake in BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after purchasing an additional 1,423 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after purchasing an additional 506 shares during the period. Sankala Group LLC bought a new stake in BioNTech in the 4th quarter valued at about $248,000. Finally, Virtu Financial LLC grew its position in shares of BioNTech by 163.9% during the 4th quarter. Virtu Financial LLC now owns 11,244 shares of the company’s stock worth $1,070,000 after purchasing an additional 6,984 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.